Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation
AssigneeGlenmark Pharmacetucals, S.A.
InventorsAbraham Thomas, Balasubramanian Gopalan, V.S. P. Lingam, Daisy Shah
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: wherein X, Y, a, R1, and R2 are as defined herein.
Claims52
A compound of general formula (I)
- wherein:
- Y is —S(O)m, —CH2—, CHF, or —CF2;
- m is 0, 1, or 2;
- X is a bond, C1-C5 alkyl, or —C(═O)—;
- the dotted line [----] in the carbocyclic ring represents an optional double bond;
- R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalklyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, CN, —COOR3, —CONR3R4, —OR3, —NR3R4, or NR3COR4;
- R2 is hydrogen, nitrile (—CN), COOH, or an isostere of a carboxylic acid;
- R3 and R4 may be the same or different and are independently hydrogen, nitro, hydroxy, cyano, formyl, acetyl, halogen, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalklyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, or a substituted or unsubstituted carboxylic acid derivative, or an analog, tautomeric form, regioisomer, stereoisomer, enantiomer, diastereomer, polymorph, solvate, N-oxide, or pharmaceutically acceptable salt thereof.
A compound according to claim 13 or 4, wherein Y is CH2.
A compound according to claim 13 oF 4, wherein Y is CHF.
A compound according to claim 1 claims 15 or 6, wherein R1 is cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, —OR3, —NR3COR4, or —NR3R4, wherein R3 and R4 may be the same or different and are independently hydrogen or substituted or unsubstituted amino.
11-45. (canceled)
A compound selected from:
- (2S)-1-{2-[(1S,4R)-4-(1H-1,2,4-Triazol-1-ylmethyl)-2-cyclopentylamino]acetyl}-pyrrolidin-2-carbonitrile,
- (2S)-1-{2-[(3SR,1RS)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-pyrrolidine-2-carbonitrile,
- (2S)-1-{2-[(3S,1R)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-pyrrolidine-2-carbonitrile,
- (2S)-1-{2-[(3R,1S)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-pyrrolidine-2-carbonitrile,
- (2S,4S)-1-{2-[(3SR,1RS)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-4-fluoropyrrolidine-2-carbonitrile,
- (2S,4S)-1-{2-[(3S,1R)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-4-fluoropyrrolidine-2-carbonitrile,
- (2S,4S)-1-{2-[(1S,3R)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-4-fluoropyrrolidine-2-carbonitrile,
- (2S,4S)-4-Fluoro-1-{2-[(1R,3R)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]-acetyl}pyrrolidin-2-carbonitrile,
- (4S)-3-{2-[(3S,1R)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-1,3-thiazolane-4-carbonitrile,
- 1-[(35)-3-Fluoropyrrolidin-1-yl]-2-[(1S,3S)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclo-pentylamino]-1-ethanone,
- and pharmaceutically acceptable salts thereof.
77-78. (canceled)
85-104. (canceled)
Dependencies are inferred from the claim text.